Related references
Note: Only part of the references are listed.Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice
Yann Ehinger et al.
NATURE COMMUNICATIONS (2021)
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study
Sarah Lapointe et al.
INVESTIGATIONAL NEW DRUGS (2020)
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
Marco A. S. Baptista et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Achondroplasia: a comprehensive clinical review
Richard M. Pauli
ORPHANET JOURNAL OF RARE DISEASES (2019)
Development of MAP4 Kinase Inhibitors as Motor Neuron-Protecting Agents
Pieter H. Bos et al.
CELL CHEMICAL BIOLOGY (2019)
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-y1})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
Denise Rageot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice
Nadege Morisot et al.
ADDICTION BIOLOGY (2018)
Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes
Qian Zhao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease
Thomas N. Chase et al.
NEUROTHERAPEUTICS (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Vanessa S. Rodrik-Outmezguine et al.
NATURE (2016)
Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation
Max A. Horlbeck et al.
ELIFE (2016)
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Zoran Rankovic
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
Christl Gaubitz et al.
MOLECULAR CELL (2015)
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2015)
Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Adverse events associated with mTOR inhibitors
Nicolas Pallet et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Evolution of the tissue selective estrogen complex (TSEC)
Barry S. Komm et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse
Segev Barak et al.
NATURE NEUROSCIENCE (2013)
Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo
Dana E. Orange et al.
ELIFE (2013)
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Iakov N Rudenko et al.
BMC Medicine (2012)
Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
Byoung Dae Lee et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Growth of kidney-transplanted pediatric patients treated with sirolimus
David Gonzalez et al.
PEDIATRIC NEPHROLOGY (2011)
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
mTOR signaling in glioblastoma: lessons learned from bench to bedside
David Akhavan et al.
NEURO-ONCOLOGY (2010)
Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders
Jeremie Neasta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Fluorescent Probes to Characterise FK506-Binding Proteins
Christian Kozany et al.
CHEMBIOCHEM (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo
Paul S. Marinec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules
Laura A. Banaszynski et al.
CELL (2006)
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response
JN Sarkaria et al.
CLINICAL CANCER RESEARCH (2006)
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
DN Franz et al.
ANNALS OF NEUROLOGY (2006)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone
TE Johnson et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors
PA Clemons et al.
CHEMISTRY & BIOLOGY (2002)
Share Paper
